Charles Link

NovaScan, Inc. engages in the development of a technology that electrically images objects. Its technology measures the electrical properties of materials. The firm focuses on breast cancer detection. The company was founded in 2001 by Larry Wells and William Gregory and is headquartered in Chicago, IL.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.

Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.

ImmunSYS, Inc. is a clinical stage biopharmaceutical company focused on the development of cancer immunotherapy products. The company was founded by Eamonn P. Hobbs and Charles J. Link Jr. in March 2018 and is headquartered in Fort Lauderdale, FL.

NovaScan, Inc. engages in the development of a technology that electrically images objects. Its technology measures the electrical properties of materials. The firm focuses on breast cancer detection. The company was founded in 2001 by Larry Wells and William Gregory and is headquartered in Chicago, IL.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.

NovaScan, Inc. engages in the development of a technology that electrically images objects. Its technology measures the electrical properties of materials. The firm focuses on breast cancer detection. The company was founded in 2001 by Larry Wells and William Gregory and is headquartered in Chicago, IL.

Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA.

Syncromune, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing an in situ platform technology optimized for metastatic solid tumor cancers. The company is based in Fort Lauderdale, FL. The company is currently developing Sync-T™, a novel combination drug/device treatment platform that aims to achieve high response rates with potentially curative efficacy. The therapy is designed to synchronize in situ neoantigen T cell education and immunostimulation via intratumoral/locoregional infusion, with the goal of enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in investigator-initiated phase 1 trials. Link. The company was founded in 2020 by Charles J. Eamonn P. Hobbs has been the CEO of the company since 2020.

Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer. The firm?s radiopharmaceutical drugs are designed to specifically localize in cancerous tissues in the human body. The company was founded by Frances L. Johnson, Michael K. Schultz and Heyward H. Coleman in 2008 and is headquartered in Coralville, IA.

NovaScan, Inc. engages in the development of a technology that electrically images objects. Its technology measures the electrical properties of materials. The firm focuses on breast cancer detection. The company was founded in 2001 by Larry Wells and William Gregory and is headquartered in Chicago, IL.